Federal Register / Vol. 82, No. 171 / Wednesday, September 6, 2017 / Notices 42121 

in which the foreign FDF will be 

compared to the company’s own 

domestically-manufactured FDF. This 

analysis is required to allow the 

company to export domesticallymanufactured FDF to foreign markets. 

Authorization will not extend to the 

import of FDA approved or nonapproved finished dosage forms for 

commercial sale. 

Dated: August 28, 2017. 

Demetra Ashley, 

Acting Assistant Administrator. 

[FR Doc. 2017–18801 Filed 9–5–17; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Fisher Clinical Services, 

Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before October 6, 2017. Such persons 

may also file a written request for a 

hearing on the application pursuant to 

21 CFR 1301.43 on or before October 6, 

2017. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All request for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on May 5, 

2017, Fisher Clinical Services, Inc., 

7554 Schantz Road, Allentown, 

Pennsylvania 18106 applied to be 

registered as an importer of the 

following basic classes of controlled 

substances: 

Controlled substance Drug 

code Schedule 

Methylphenidate ...................... 1724 II 

Levorphanol ............................ 9220 II 

Noroxymorphone .................... 9668 II 

Tapentadol .............................. 9780 II 

The company plans to import the 

listed controlled substances for 

analytical research, testing, and clinical 

trials. This authorization does not 

extend to the import of a finished FDA 

approved or non-approved dosage form 

for commercial distribution in the 

United States. 

The company plans to import an 

intermediate form of tapentadol (9780) 

to bulk manufacture tapentadol for 

distribution to its customers. Placement 

of these (this) drug code(s) onto the 

company’s registration does not 

translate into automatic approval of 

subsequent permit applications to 

import controlled substances. Approval 

of permit applications will occur only 

when the registrant’s business activity is 

consistent with what is authorized 

under to 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of FDA approved or nonapproved finished dosage forms for 

commercial sale. 

Dated: August 28, 2017. 

Demetra Ashley, 

Acting Assistant Administrator. 

[FR Doc. 2017–18785 Filed 9–5–17; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Foreign Claims Settlement 

Commission 

[F.C.S.C. Meeting and Hearing Notice No. 

8–17] 

Sunshine Act Meeting 

The Foreign Claims Settlement 

Commission, pursuant to its regulations 

(45 CFR part 503.25) and the 

Government in the Sunshine Act (5 

U.S.C. 552b), hereby gives notice in 

regard to the scheduling of open 

meetings as follows: 

DATES: THURSDAY, SEPTEMBER 14, 2017: 

10:00 a.m.—Issuance of Proposed 

Decisions in claims against Iraq. 

STATUS: Open. 

All meetings are held at the Foreign 

Claims Settlement Commission, 600 E 

Street NW., Washington, DC. Requests 

for information, or advance notices of 

intention to observe an open meeting, 

may be directed to: Patricia M. Hall, 

Foreign Claims Settlement Commission, 

600 E Street NW., Suite 6002, 

Washington, DC 20579. Telephone: 

(202) 616–6975. 

Brian M. Simkin, 

Chief Counsel. 

[FR Doc. 2017–18962 Filed 9–1–17; 11:15 am] 

BILLING CODE 4410–BA–P 

DEPARTMENT OF JUSTICE 

[OMB Number 1122–0011] 

Agency Information Collection 

Activities; Proposed eCollection 

eComments Requested; Extension of a 

Currently Approved Collection 

AGENCY: Office on Violence Against 

Women, Department of Justice. 

ACTION: 60-Day notice. 

SUMMARY: The Department of Justice, 

Office on Violence Against Women 

(OVW) will be submitting the following 

information collection request to the 

Office of Management and Budget 

(OMB) for review and approval in 

accordance with the Paperwork 

Reduction Act of 1995. 

DATES: Comments are encouraged and 

will be accepted for 60 days until 

November 6, 2017. 

FOR FURTHER INFORMATION CONTACT: 

Written comments and/or suggestion 

regarding the items contained in this 

notice, especially the estimated public 

burden and associated response time, 

should be directed to Cathy Poston, 

Office on Violence Against Women, at 

202–514–5430 or Catherine.poston@

usdoj.gov. 

SUPPLEMENTARY INFORMATION: Written 

comments and suggestions from the 

public and affected agencies concerning 

the proposed collection of information 

are encouraged. Your comments should 

address one or more of the following 

four points: 

(1) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 


asabaliauskas on DSKBBXCHB2PROD with NOTICES